Your browser doesn't support javascript.
loading
CRISPR deletions in cell lines for reconstitution studies of pseudokinase function.
Jacobsen, Annette V; Murphy, James M.
Afiliación
  • Jacobsen AV; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
  • Murphy JM; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia. Electronic address: jamesm@wehi.edu.au.
Methods Enzymol ; 667: 229-273, 2022.
Article en En | MEDLINE | ID: mdl-35525543
ABSTRACT
The non-catalytic cousins of protein kinases, the pseudokinases, have grown to prominence as indispensable signaling entities over the past decade, despite their lack of catalytic activity. Because their importance has only been fully embraced recently, many of the 10% of the human kinome categorized as pseudokinases are yet to be attributed biological functions. The advent of CRISPR-Cas9 editing to genetically delete pseudokinases in a cell line of interest has proven invaluable to dissecting many functions and remains the method of choice for gene knockout. Here, using the terminal effector pseudokinase in the necroptosis cell death pathway, MLKL, as an exemplar, we describe a method for genetic knockout of pseudokinases in cultured cells. This method does not retain the CRISPR guide sequence in the edited cells, which eliminates possible interference in subsequent reconstitution studies where mutant forms of the pseudokinase can be reintroduced into cells exogenously for detailed mechanistic characterization.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Proteínas Quinasas / Sistemas CRISPR-Cas / Edición Génica Límite: Humans Idioma: En Revista: Methods Enzymol Año: 2022 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Proteínas Quinasas / Sistemas CRISPR-Cas / Edición Génica Límite: Humans Idioma: En Revista: Methods Enzymol Año: 2022 Tipo del documento: Article País de afiliación: Australia